Emergent BioSolutions Inc. — Director's Dealing 2021

Jan 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2021-01-20

Reporting Person: Kramer Robert (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-20	Common Stock	M	2232	$26.45	Acquired	141442	Direct
2021-01-20	Common Stock	S	2232	$110	Disposed	139210	Direct
2021-01-21	Common Stock	M	21900	$26.45	Acquired	161110	Direct
2021-01-21	Common Stock	S	21900	$110.03	Disposed	139210	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-20	Employee Stock Options (Right to Buy)	$26.45	M	2232	Disposed	2022-03-09	Common Stock (2232.0)	Direct
2021-01-21	Employee Stock Options (Right to Buy)	$26.45	M	21900	Disposed	2022-03-09	Common Stock (21900.0)	Direct

Footnotes

F1: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated.

F2: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F3: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.36.

F4: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.